Topical Tranexamic Acid for Total Knee Arthroplasty

Three million (1 in 10) Canadians suffer from Osteoarthritis (OA). Total knee arthroplasty (TKA), i.e. knee replacement surgery is the definitive treatment for knee osteoarthritis which alleviates pain and restores physical functioning. However, it can be associated with excessive postoperative bleeding leading to increased mortality and morbidity. The current blood conservation techniques, i.e. preoperative erythropoietin and autologous blood donation, do not reduce bleeding from the surgical site. As a result, many patients require blood transfusion with the associated risks and costs. In TKA, postoperative bleeding is attributed to diffuse microvascular bleeding as a result of increased fibrinolytic activity caused by releasing of the tourniquet which is routinely applied to provide appropriate surgical exposure during surgery. Therefore, tranexamic acid (TA), an antifibrinolytic agent which blocks the dissolution of hemostatic fibrin, can decrease blood loss following TKA. The systemic administration of TA, however, carries the risk of thromboembolic events such as deep vein thrombosis (DVT) or pulmonary embolism (PE). In TKA, this is of greater importance, as the patients are at higher risk of thromboembolic events. Topical application of TA in the surgical field is a cost-effective and simple route of administration that has been shown to reduce bleeding in dental, cardiac, and spine surgeries while minimizing systemic absorption and thromboembolism. Another major advantage of this approach is to prevent diffuse microvascular bleeding at the site of raw tissue surfaces resulting in decreased infection rate, pain, and increased range of motion (ROM) of the knee joints. In spite of these potential benefits, the innovative idea of topical application of TA has not been studied in TKA. However, if it is shown to be efficacious in decreasing postoperative bleeding, it can be incorporated into routine clinical practice with immediate beneficial impacts on patient care and quality of life.

Hypothesis:

In patients undergoing unilateral primary/revision TKA, intraoperative application of 1.5 g or 3 g topical TA into the surgical wound for five minutes before closure reduces perioperative bleeding as depicted by the maximal drop in systemic hemoglobin concentration during the postoperative period.

General Objective:

To study the role of tranexamic acid as a therapeutic tool, applied intraoperatively into the surgical wound, to reduce perioperative blood loss in patients undergoing a unilateral primary/revision TKA.

Specific Objectives:

To determine:

• the efficacy of topical application of TA to reduce perioperative transfusion requirements.
• the safety of topical application of TA (complications such as DVT).
• the systemic absorption of TA after topical application into the surgical wound.
• the impact of postoperative hemoglobin (Hb) reduction on patients' quality of life.
• the impact of topical application of TA on the length of hospital stay.
• the impact of topical application of TA on ROM, pain, and surgical infection rate of the knee joint.
• the incidence of autologous and allogenic blood transfusion in patients receiving the standard.
• multimodal blood conservation techniques for TKA surgery at our institution
• to compare the efficacy and safety of high dose (3 g) of TA versus low dose (1.5 g) of TA.

Inclusion criteria

• All adult patients (greater than 18 years old).
• Patients scheduled for primary unilateral total knee arthroplasty.

Exclusion criteria

• Allergy to tranexamic acid
• Acquired disturbances of color vision
• Preoperative anemia (hemoglobin <110 in females; hemoglobin <120 in males)
• Refusal of blood products (Jehovah's witnesses),
• Preoperative use of anticoagulant therapy - coumadin, heparin within 5 days of surgery, fibrinolytic disorders requiring intraoperative antifibrinolytic treatment,
• Coagulopathy (preoperative platelet count < 150,000/mm3, INR >1.4, prolonged PTT (>1.4 x normal))
• A previous history of thromboembolic disease (e.g. CVA, DVT or PE)
• Pregnancy
• Breastfeeding
• Significant co-morbidities:
• severe ischemic heart disease; NYHA Class III, IV,
• previous myocardial infarction
• severe pulmonary disease, e.g. FEV1<50% normal,
• plasma creatinine greater than 115 µmol/l in males and more than 100 µmol/l in females
• hepatic failure
• Intraoperative surgical/medical/anesthetic complications occur, e.g. MI, intraoperative bone fracture or neurovascular injury